Marker Therapeutics Files 2024 10-K
Ticker: MRKR · Form: 10-K · Filed: Mar 31, 2025 · CIK: 1094038
| Field | Detail |
|---|---|
| Company | Marker Therapeutics, Inc. (MRKR) |
| Form Type | 10-K |
| Filed Date | Mar 31, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceuticals, financials
TL;DR
Marker Therapeutics filed its 2024 10-K, detailing financials for the year ending Dec 31, 2024.
AI Summary
Marker Therapeutics, Inc. filed its 2024 10-K on March 31, 2025, reporting its fiscal year ending December 31, 2024. The company, formerly known as TAPIMMUNE INC. and GENEMAX CORP, is based in Houston, TX. The filing details its financial performance and business operations for the year.
Why It Matters
This 10-K filing provides investors and stakeholders with a comprehensive overview of Marker Therapeutics' financial health and strategic direction for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Marker Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-03-31 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- Marker Therapeutics, Inc. (company) — Filer
- TAPIMMUNE INC. (company) — Former Company Name
- GENEMAX CORP (company) — Former Company Name
- 2024-12-31 (date) — Fiscal Year End
- 20250331 (date) — Filing Date
- Houston, TX (location) — Business Address
FAQ
What was Marker Therapeutics' primary business focus during the fiscal year 2024?
The filing indicates Marker Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC 2834), suggesting a focus on drug development and related activities.
When did Marker Therapeutics change its name from its previous entities?
Marker Therapeutics was formerly known as TAPIMMUNE INC. with a name change date of 20170629, and prior to that, GENEMAX CORP with a name change date of 20020718.
What is the company's principal executive office location?
The company's business address is located at 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, TX 77021.
What is the SEC file number for Marker Therapeutics?
The SEC file number for Marker Therapeutics, Inc. is 001-37939.
What specific financial statement items are mentioned with dates in the provided text?
The filing mentions us-gaap:ResearchMember for 2024-12-31, us-gaap:CommonStockMember for 2022-12-01 to 2023-01-31, us-gaap:CommonStockMember and us-gaap:PrivatePlacementMember for 2024-12-19, us-gaap:RetainedEarningsMember for 2024-12-31, and us-gaap:AdditionalPaidInCapitalMember for 2024-12-31.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 31, 2025 regarding Marker Therapeutics, Inc. (MRKR).